华海药业(600521.SH)子公司HB0017注射液上市许可申请获得受理

智通财经06-25

智通财经APP讯，华海药业(600521.SH)发布公告，近日，公司下属子公司上海华奥泰生物药业股份有限公司(简称“华奥泰”)收到国家药品监督管理局签发的HB0017注射液境内生产药品注册上市许可申请的《受理通知书》。申报适应症：用于治疗适合接受系统治疗或光疗的中度至重度斑块状银屑病成人患者。

HB0017注射液是华奥泰自主研发的以白介素-17A(IL-17A)为靶点的单克隆抗体，拟用于治疗中重度斑块状银屑病(境内注册上市申请已受理)、强直性脊柱炎(推进III期临床)及其他自身免疫疾病。截至目前，公司在HB0017注射液项目上的研发投入合计约人民币45,403万元。

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2646768798?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-06-25 17:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2646768798","market":"us","top_or_hot":-1,"title":"华海药业(600521.SH)子公司HB0017注射液上市许可申请获得受理","media":"智通财经","content":"<html><body><p>智通财经APP讯，<a href=\"https://laohu8.com/S/600521\">华海药业</a>(600521.SH)发布公告，近日，公司下属子公司上海华<a href=\"https://laohu8.com/S/688606\">奥泰生物</a>药业股份有限公司(简称“华奥泰”)收到国家药品监督管理局签发的HB0017注射液境内生产药品注册上市许可申请的《受理通知书》。申报适应症：用于治疗适合接受系统治疗或光疗的中度至重度斑块状银屑病成人患者。</p><p>HB0017注射液是华奥泰自主研发的以白介素-17A(IL-17A)为靶点的单克隆抗体，拟用于治疗中重度斑块状银屑病(境内注册上市申请已受理)、强直性脊柱炎(推进III期临床)及其他自身免疫疾病。截至目前，公司在HB0017注射液项目上的研发投入合计约人民币45,403万元。</p></body></html>","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>华海药业(600521.SH)子公司HB0017注射液上市许可申请获得受理</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n华海药业(600521.SH)子公司HB0017注射液上市许可申请获得受理\n</h2>\n\n<h4 class=\"meta\">\n\n</h4>\n\n</header>\n<article>\n<html><body><p>智通财经APP讯，<a href=\"https://laohu8.com/S/600521\">华海药业</a>(600521.SH)发布公告，近日，公司下属子公司上海华<a href=\"https://laohu8.com/S/688606\">奥泰生物</a>药业股份有限公司(简称“华奥泰”)收到国家药品监督管理局签发的HB0017注射液境内生产药品注册上市许可申请的《受理通知书》。申报适应症：用于治疗适合接受系统治疗或光疗的中度至重度斑块状银屑病成人患者。</p><p>HB0017注射液是华奥泰自主研发的以白介素-17A(IL-17A)为靶点的单克隆抗体，拟用于治疗中重度斑块状银屑病(境内注册上市申请已受理)、强直性脊柱炎(推进III期临床)及其他自身免疫疾病。截至目前，公司在HB0017注射液项目上的研发投入合计约人民币45,403万元。</p></body></html>\n\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"http://www.zhitongcaijing.com/content/detail/1458715.html\">智通财经</a> </p>\n\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n</div>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0028","symbol_name":"国家队","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1458715.html","article_id":"2646768798","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2646768798","pubTimestamp":1782379348,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP讯，华海药业(600521.SH)发布公告，近日，公司下属子公司上海华奥泰生物药业股份有限公司(简称“华奥泰”)收到国家药品监督管理局签发的HB0017注射液境内生产药品注册上市许可申请的《受理通知书》。申报适应症：用于治疗适合接受系统治疗或光疗的中度至重度斑块状银屑病成人患者。HB0017注射液是华奥泰自主研发的以白介素-17A(IL-17A)为靶点的单克隆抗体，拟用于治疗中重度斑块状银屑病(境内注册上市申请已受理)、强直性脊柱炎(推进III期临床)及其他自身免疫疾病。截至目前，公司在HB0017注射液项目上的研发投入合计约人民币45,403万元。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"600521":"华海药业","BK0028":"国家队","IPOS":"Renaissance International IPO ETF","BK0185":"二线龙头","BK0239":"医药制造","BK0201":"可转债","BK0070":"员工持股","BK0188":"融资融券","BK0012":"证金概念"},"translate_title":"Huahai Pharmaceutical (600521.SH) Subsidiary HB0017 Injection Marketing Authorization Application Accepted","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600521":1.5,"IPOS":1.5},"content_text":"智通财经APP讯，华海药业(600521.SH)发布公告，近日，公司下属子公司上海华奥泰生物药业股份有限公司(简称“华奥泰”)收到国家药品监督管理局签发的HB0017注射液境内生产药品注册上市许可申请的《受理通知书》。申报适应症：用于治疗适合接受系统治疗或光疗的中度至重度斑块状银屑病成人患者。HB0017注射液是华奥泰自主研发的以白介素-17A(IL-17A)为靶点的单克隆抗体，拟用于治疗中重度斑块状银屑病(境内注册上市申请已受理)、强直性脊柱炎(推进III期临床)及其他自身免疫疾病。截至目前，公司在HB0017注射液项目上的研发投入合计约人民币45,403万元。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2646768798","isCrawlerRequest":true}